NeuroSense Therapeutics Ltd — Cash Flow (NASDAQ:NRSN) | MetaTrader

Open full chart

Financials

Overview Finanzbericht Statistics Dividends

Quarterly Annual

Cash from operating activities 1.54 M7.59 M8.45 M10.13 M — Cash from investing activities 17 K3.54 M3.65 M1 000 — Cash from financing activities 11.9 M3.69 M3.9 M10.91 M — Free cash flow 1.54 M7.59 M8.45 M10.13 M —

Nachrichten

Neurosense-Aktie legt nach Patent-Erfolg in Australien zu

Neurosense Therapeutics stock rises after securing Australian patent for PrimeC

Positive Sicherheitsdaten zu Alzheimer-Medikament treiben NeuroSense-Aktie an

Neurosense stock rises as Alzheimer’s drug shows favorable safety profile

NRSN stock touches 52-week high at $1.65 amid robust gains

NRSN stock touches 52-week high at $1.52 amid growth optimism

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights - NeuroSense Therapeutics (NASDAQ:NRSN)

This NeuroSense Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday - NeuroSense Therapeutics (NASDAQ:NRSN), Primis Finl (NASDAQ:FRST)